CLCS Cell Source, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1569340 · Fiscal year ends 12/31
Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.8%
TTM EPS YoY12.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,516.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6,985.4%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-857.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| SG&A expense | $1.94M | $2.60M |
| Operating income | -$3.84M | -$4.33M |
| Pretax income | -$4.51M | -$5.32M |
| Net income | -$4.51M | -$5.32M |
| EPS (basic) | -0.14 | -0.17 |
| EPS (diluted) | -0.14 | -0.17 |
| Weighted avg. shares (diluted) | 41.87M | 37.79M |
| Balance sheet | ||
| Cash & equivalents | $74,631 | $22,203 |
| Total assets | $286,500 | $195,171 |
| Total liabilities | $18.82M | $15.81M |
| Shareholders' equity | -$18.54M | -$15.61M |
| Shares outstanding | 45.04M | 39.83M |
| Cash flow statement | ||
| Operating cash flow | -$2.68M | -$2.35M |
| Financing cash flow | $2.74M | $2.15M |
| Stock-based compensation | $288,424 | $463,034 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.